Pulmonx Announces Publication of CONVERT Trial Results for AeriSeal® System
Key Highlights
- ➤75.8% of evaluable patients converted collateral ventilation-positive lobes to negative.
- ➤88.9% achieved clinically significant target-lobe volume reduction at 45 days.
- ➤Zephyr Valve treatment benefits persisted through 12 months after conversion.
- ➤CONVERT II enrolling approximately 200 patients to support a U.S. PMA application.
- ➤Pulmonx plans six-month CONVERT II results to support AeriSeal FDA approval.
Expert Statements
Michela Bezzi, Director Interventional Pulmonology, ASST Spedali Civili, University Hospital, Brescia, Italy
“The CONVERT results are very encouraging because they demonstrate the potential to overcome one of the important barriers preventing patients with severe emphysema from benefiting from bronchoscopic lung volume reduction”
Michela Bezzi, Director Interventional Pulmonology, ASST Spedali Civili, University Hospital, Brescia, Italy
“By converting collateral ventilation status and then successfully treating these patients with Zephyr Valves, we may be able to offer a minimally invasive treatment option to an additional group of patients who today have limited options.”
Glen French, President and Chief Executive Officer of Pulmonx
“The publication of the CONVERT results represents an important milestone in our efforts to help a larger number of severe emphysema patients who may benefit from Zephyr Valve treatment.”
Glen French, President and Chief Executive Officer of Pulmonx
“CONVERT demonstrated that approximately three out of four evaluable patients could have lobes converted from collateral ventilation positive to collateral ventilation negative status.”
REDWOOD CITY, Calif., Nov. 17, 2026 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx” or the “Company”), a global leader in minimally invasive treatments for chronic obstructive pulmonary disease (COPD), today announced the online publication of results from the CONVERT Trial evaluating the AeriSeal® System in patients with severe emphysema and collateral ventilation, in Respiration: International Journal of Thoracic Medicine.
Bronchoscopic lung volume reduction with Zephyr® Endobronchial Valves is effective in patients with little to no collateral ventilation (CV-) in the targeted lung lobe. Collateral ventilation (CV+) allows airflow through openings in the fissures between lung lobes and can prevent a targeted lobe from reducing in volume following valve placement. The CONVERT Trial evaluated whether targeted treatment with the AeriSeal System could close these collateral channels and convert lobes from CV+ to CV- status, potentially enabling subsequent treatment with Zephyr Valves. The CONVERT study was conducted at 14 investigational sites in Europe and Australia and included 101 patients in the intent-to-treat population.
Get started
Create a free account to read the full story.
